Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome

• Autores: Chen Li, Zhaohui Li, Yihan Cao, Li Li, Feng Li, Yueting Li, Dingkun Xiong, Xia Wu, Wen Zhang, Xiaofeng Zeng
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 157, Nº. 1, 2021, págs. 74-78
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance Nail involvement is common in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, which has a strong association with quality of life in patients with SAPHO. Tofacitinib is an oral Janus kinase inhibitor that has been previously shown to be effective for nail psoriasis.

    Objective To assess the efficacy and safety of tofacitinib for the treatment of nail involvement in SAPHO syndrome.

    Interventions Participants received tofacitinib, 5 mg, twice daily, for 12 weeks.

    Design, Setting, and Participants This open-label, single-arm, prospective pilot study included 13 patients with SAPHO syndrome accompanied by nail lesions and active palmoplantar pustulosis who were recruited from Peking Union Medical College Hospital from September 2019 to December 2019. Follow-up was completed in March 2020. Analysis began March 2020 Main Outcomes and Measures The primary end point was the percentage of the change from baseline in Nail Psoriasis Severity Index scores at week 12. Secondary end points included the percentage of the change from baseline in Palmoplantar Psoriasis Area and Severity Index scores, change from baseline in Visual Analogue Scale scores in global osteoarticular pain, Dermatology Life Quality Index scores, and inflammatory markers. Adverse events were recorded throughout the study.

    Results Thirteen female Asian patients (means [SD] age, 39.7 [12.3] years) were included, all of whom completed the study. At week 12, significant improvements were observed in Nail Psoriasis Severity Index scores (median, −67% [interquartile range (IQR), −56% to −77%]; P < .001) and Palmoplantar Psoriasis Area and Severity Index scores (median, −71% [IQR, −58% to −78%]; P < .001). Significant improvement was also noted in Dermatology Life Quality Index scores (median, −12 [IQR, −8.5 to −15]; P < .001) at week 12. A significant decrease in Visual Analogue Scale scores in global osteoarticular pain was observed at week 8 (median, −4 [IQR, 0 to −5]; P = .02) but was not significant at week 12. Inflammatory marker levels were decreased, as indicated by erythrocyte sedimentation rate (median, −8 mm/h [IQR, −4 mm/h to −11 mm/h]; P < .001) and high-sensitivity C-reactive protein levels (median, −1.6 [IQR, −0.3 to −4.1]; P = .01). No severe adverse events were observed. Conclusions and Relevance In this pilot study, tofacitinib yielded significant remission of nail lesions and palmoplantar psoriasis accompanied by an improvement in quality of life in patients with SAPHO syndrome. Additional follow-up studies to evaluate the long-term efficacy and safety of tofacitinib for nail involvement in SAPHO syndrome are warranted.